Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Zosano Pharma Corporation
FREMONT, Calif., June 25, 2014 /PRNewswire/ -- Zosano Pharma Corporation, a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced the election of Troy Wilson, Ph.D., J.D., to its Board of Directors. Dr. Wilson has more than 15 years of experience in the biotechnology industry and a proven track record of building highly successful biopharmaceutical companies. The appointment increases Zosano Pharma's board membership to six.
"Zosano is very pleased to have Troy join our board as an independent director," said Bruce Steel, Chairman of the Board of Directors of Zosano Pharma. "He is an innovative and entrepreneurial CEO with an extensive and successful track record in the healthcare industry. We look forward to his guidance and insights as Zosano pursues execution and advancement of its clinical development programs."
Dr. Wilson is the President and Chief Executive Officer, co-founder and a member of the board of managers of Avidity NanoMedicines and Wellspring Biosciences. He previously served as President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc., a company that he co-founded until that company's acquisition by Takeda Pharmaceuticals in 2012. Prior to starting Intellikine, Dr. Wilson was co-founder and Chief Business Officer of Ambrx, Inc. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley. He serves as Director of Puma Biotechnology, Inc. as well as a member of the board of managers of Araxes Pharma LLC, a private biopharmaceutical company.
"I am delighted to join the Zosano Board," said Dr. Wilson. "Zosano's novel ZP Patch Technology has the potential to improve a patient's experience with drugs that require rapid onset and a more convenient means of delivery – and I look forward to working with the other Board members and the management team to maximize the value of the company and its technology."
About Zosano Pharma Corporation
Zosano Pharma Corporation is a privately held biopharmaceutical company and a pioneer in the field of transdermal drug delivery. Zosano is developing products with a rapid onset using its proprietary microneedle patch system. Zosano seeks to develop products with significant commercial potential both independently and in collaboration with strategic partners. Zosano's microneedle patch delivers therapeutic compounds through the skin and provides rapid systemic drug delivery in a convenient, needle–free and pain–free system. Zosano's microneedle patch system has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.
©2012 PR Newswire. All Rights Reserved.